A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial

✍ Scribed by Claire E. Dearden; Sue Richards; Monica Else; Daniel Catovsky; Peter Hillmen

• Publisher: John Wiley and Sons
• Year: 2010
• Tongue: English
• Weight: 220 KB
• Volume: 117
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/cncr.25776

✦ Synopsis

Abstract

BACKGROUND:

An oral formulation of fludarabine was introduced for use in chronic lymphocytic leukemia in 2001 following studies demonstrating the bioequivalence of a 40 mg/m^2^ oral dose with a 25 mg/m^2^ intravenous dose. We assessed retrospectively the efficacy of these two routes of administration in the LRF CLL4 trial.

METHODS:

A total of 777 patients were randomized from 1999‐2004 to receive fludarabine, alone or with cyclophosphamide, or chlorambucil. In 2001, a protocol amendment allowed the oral formulation. There were 117 assessable patients who received fludarabine intravenously and 252 who received it orally. A total of 387 patients given chlorambucil acted as a control group.

RESULTS:

Patients given oral fludarabine were less likely to receive the full dose (P = .0004) and experienced more, predominantly gastrointestinal, toxicity. Progression‐free survival (PFS) and overall survival were not affected by the route of administration (PFS hazard ratio, 1.10; 95% confidence interval, 0.87‐1.40), but the overall rate of response to treatment appeared to be lower with the oral formulation (P = .003). However, patients recruited since 2001 were older (P = .03) and were more likely to have TP53 deletion, and response rates after 2001 were also lower in the chlorambucil group. After excluding patients with TP53 deletion, no significant difference in outcome was attributable to the route of administration.

CONCLUSIONS:

Although the LRF CLL4 data suggest no important difference in the effectiveness of oral compared with intravenous fludarabine, randomized trials are needed to reliably evaluate this comparison, particularly in combination with rituximab. Meanwhile, it is important to monitor compliance and gastrointestinal side effects with the oral route and to switch to intravenous therapy if a reduced dose is being received. Cancer 2011. © 2010 American Cancer Society.